Clinical Trials · NCT00050635
STOP Trial - Sandostatin LAR Depot Trial for the Optimum Prevention of Chemotherapy Induced Diarrhea
- Phase
- Phase 4
- Recruitment status
- Completed
- Sponsor
- Novartis Pharmaceuticals
- Enrollment
- 150
- Start date
- Dec 2002
- Locations
- 34 sites, United States
- Primary endpoint
- Change from baseline and at 6 months in the proportion of patients with NCI Grades 3 and/or 4 diarrhea during chemotherapy